JADE101 Enters Phase 2 for IgA Nephropathy; Jade Biosciences Doses First Patient
JBIO has more than doubled off its 52-week low of $6.565.
Summary
Jade Biosciences announced the dosing of the first participant in its Phase 2 JUNIPER clinical trial for JADE101, a drug targeting IgA Nephropathy. This is a key pipeline advancement for the clinical-stage biotech, moving its lead candidate further into human trials. The progress is particularly important given the company's recent Q1 2026 report of increased losses and a $200 million 'at the market' offering to raise capital. Interim data from the JUNIPER trial are anticipated in 2027.
At the time of this announcement, JBIO was trading at $22.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $6.57 to $28.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.